Introduction {#s1}
============

The development of atrioventricular (AV) block requiring permanent pacemaker (PPM) implantation is a well-known complication of transcatheter aortic valve replacement (TAVR) \[[@R01]-[@R04]\]. Rates of PPM implantation after TAVR are variably reported in the literature and are influenced by multiple factors, including the type of valve used as well as procedural and patient-specific risk factors \[[@R05], [@R06]\]. Aortic valve calcification as quantified on pre-TAVR computed tomography (CT) scans has been proposed as a novel and highly predictive risk factor of PPM implantation after TAVR \[[@R07]\].

The mechanism of conduction disturbances following TAVR is incompletely understood, contributing to the difficulty in predicting which patients will require PPM implantation after the procedure. The mechanical stress of deployment and resultant tissue edema are thought to be possible contributors, resulting in possible injury to the nearby AV node and left bundle branch \[[@R08], [@R9]\]. Multiple studies have reported eventual recovery of intrinsic conduction in a significant portion of patients who received PPM after TAVR, sometimes as early as 10 days post-implantation \[[@R10]-[@R13]\]. Because the decision to move forward with PPM implantation after TAVR can have significant clinical and economic ramifications, identifying the possibility of conduction system recovery after TAVR would be helpful in guiding management strategies regarding pacemaker implantation \[[@R14]-[@R16]\].

Though many studies have examined risk factors for PPM implantation after TAVR, few have looked at risk factors for pacemaker dependence after the procedure, especially within the first 30 days post-procedure. In this study, the utility of aortic valve calcification as quantified on CT scan as a predictor for the need for right ventricular (RV) pacing after TAVR is examined.

Materials and Methods {#s2}
=====================

Study population {#s2a}
----------------

The study population consisted of 262 consecutive patients who underwent TAVR at a single center from March 2012 to October 2016. Prior to TAVR, all patients underwent coronary angiography, computed tomographic angiography of the chest, abdomen, and pelvis, and 2D echocardiography. A multidisciplinary team consisting of at least two cardiothoracic surgeons and an interventional cardiologist then evaluated the patients and accepted them for TAVR. All patients received a balloon-expandable Edwards SAPIEN valve (Edwards Life Sciences, Inc.). Three different generations of the SAPIEN valves were used in this study: SAPIEN, SAPIEN XT and SAPIEN III ([Table 1](#T1){ref-type="table"}). Thirty-six patients with PPM implantation prior to the TAVR were excluded from the study cohort. No patients met guideline indications for permanent pacing prior to TAVR.

###### Electrocardiographic Data, Clinical Imaging Data and Procedural Parameters of Non-RV Pacing-Dependent and RV Pacing-Dependent Patients at 1 Month Post-PPM Implant

                                                Non-RV pacing-dependent (n = 17)   RV pacing-dependent (n = 8)   P-value
  --------------------------------------------- ---------------------------------- ----------------------------- -----------
  Electrocardiographic data                                                                                      
    Sinus                                       11/17                              7/8                           0.36
    First-degree AV block                       3/17                               2/8                           1
    LAFB                                        4/17                               3/8                           0.64
    LPFB                                        1/17                               1/8                           1
    RBBB                                        2/17                               8/8                           \< 0.0001
    LBBB                                        1/17                               0/8                           1
    Bifascicular block                          2/17                               5/8                           0.017
    QRS duration \> 120 ms                      3/17                               8/8                           0.0002
    QRS duration (ms)                           108.4 ± 22.0                       138.8 ± 14.1                  0.0017
  Clinical imaging data                                                                                          
    Aortic valve area^a^                        0.65 ± 0.23                        0.77 ± 0.26                   0.23
    LVEF^a^                                     52.1 ± 13.9                        59.4 ± 11.8                   0.21
    LVOTd^a^                                    2.04 ± 0.33                        2.10 ± 0.22                   0.64
    LVEDd^a^                                    4.94 ± 0.80                        4.64 ± 0.84                   0.43
    Aortic annulus diameter^b^                  2.37 ± 0.30                        2.51 ± 0.22                   0.25
    Aortic annulus area^b^                      4.48 ± 1.12                        5.06 ± 0.79                   0.21
    Severe MAC                                  4/17                               0/8                           0.28
  Procedural parameters                                                                                          
    Transfemoral approach                       13/17                              8/8                           0.27
    Transapical approach                        4/17                               0/8                           0.27
    Intra-procedural complete heart block       6/17                               7/8                           0.03
    Valve size                                  25.3 ± 2.5                         25.3 ± 2.1                    0.97
    Valve/LVOTd^a^                              12.6 ± 1.8                         12.1 ± 1.1                    0.45
    Days post-TAVR of pacemaker insertion       5.24 ± 3.44                        5.88 ± 6.31                   0.74
    Paravalvular leak requiring post-dilation   7/17                               1/8                           0.21
    Percent oversizing by annulus area^b^       13.7 ± 15.3                        -0.03 ± 12.7                  0.04
    Generation                                                                                                   
      SAPIEN                                    12/17                              5/8                           1
      SAPIEN XT                                 3/17                               0/8                           0.53
      SAPIEN III                                2/17                               3/8                           0.28
    Pacemaker indication                                                                                         
      CHB                                       12/17                              8/8                           0.14
      SSS                                       3/17                               0/8                           0.53
      New LBBB                                  2/17                               0/8                           0.55

The P-values shown are derived from two-tailed Fisher's exact test for categorical variables and two-tailed unpaired Student's *t*-test for continuous variables. Patients who were non-RV pacing-dependent at 30 days and patients who were RV pacing-dependent at 30 days patients were separately compared with the non-pacemaker population to derive these P-values. Continuous variables are reported as the mean plus or minus the standard deviation. ^a^Values obtained by transthoracic echocardiography. ^b^Values obtained by multidetector computed tomography. RV: right ventricular; PPM: permanent pacemaker; AV: atrioventricular; LAFB: left anterior fascicular block; LPFB: left posterior fascicular block; RBBB: right bundle branch block; LBBB: left bundle branch block; LVEF: left ventricular ejection fraction; LVEDd: left ventricular end diastolic diameter; LVOTd: left ventricular outflow tract diameter; MAC: mitral annular calcification; TAVR: transcatheter aortic valve replacement; CHB: complete heart block; SSS: sick sinus syndrome; LVOT: left ventricular outflow tract.

Patient characteristics {#s2b}
-----------------------

Baseline demographic, electrocardiographic, procedural and imaging data were collected on each patient as part of the routine pre-TAVR workup. All electrocardiography (ECG) data were obtained based on pre-operative 12-lead ECGs obtained during the index admission within 24 h prior to TAVR. Data regarding intra-procedural parameters were obtained from the procedure notes.

Pacemaker and interrogation data {#s2c}
--------------------------------

All patients who received PPM implants met guideline indications for post-procedural permanent pacing at the time of implantation, as determined by a consulting board-certified electrophysiologist. Patients did not receive an EP study prior to a decision being made regarding PPM implantation. The most common indication for pacemaker implantation was complete heart block (CHB) ([Fig. 1](#F1){ref-type="fig"}). These patients had cardiology follow-up within 10 days and an additional follow-up within 1 month after implantation. Pacing and underlying rhythm data were obtained during device interrogations at these visits. Patients were considered pacemaker-dependent if their spontaneous ventricular rate was less than 30 beats/min during backup pacing set at 30 beats/min for 30 s, as done in prior studies \[[@R10], [@R17]\].

![A total of 262 patients underwent transcatheter aortic valve replacement (TAVR), 36 patients were excluded from analysis because of pre-existing pacemakers and 25 patients required pacemaker implantation after TAVR for three different indications. All patients received a pacemaker check at 10 and 30 days. At 10 days, nine patients were no longer right ventricular (RV) pacing-dependent. At 30 days, 17 patients were no longer RV pacing-dependent. CHB: complete heart block; SSS: sick sinus syndrome; LBBB: left bundle branch block; PPM: permanent pacemaker.](cr-11-155-g001){#F1}

Multidetector computed tomography (MDCT) image acquisition {#s2d}
----------------------------------------------------------

An electrocardiographically gated multidetector CT study was performed only if the patient's renal function was considered satisfactory, as is routine clinical practice; this was generally when the serum creatinine was ≤ 2.0 mg/dL. Patients were evaluated using a Siemens Somatom Cardiac 64 or Siemens Somatom Flash scanner (Siemens Medical Solutions USA, Inc., Malvern, PA) using collimation of 0.6 mm at a fixed pitch of 0.2 with an injection of 50 to 110 mL of iopamidol (Isovue-370). A dedicated protocol was formulated, with 120 kV and tube current modified according to the patient's size. Image acquisition was, for the most part, performed with retrospective electrocardiographic gating. CT Digital Imaging and Communications in Medicine (DICOM) data were analyzed by a dedicated advanced imaging core laboratory using TeraRecon Aquarius software (San Mateo, CA).

Analysis of aortic valve complex calcification {#s2e}
----------------------------------------------

The protocol for analysis of aortic valve complex calcification used in this study was modified from existing published reports \[[@R07], [@R18]\]. The aortic annulus was defined as the virtual plane that contained the basal points of attachment of all three aortic valve leaflets in the proximal left ventricular outflow tract (LVOT). The late systolic phase (35% of the R-R interval) was used during image analysis for best image quality. Calcium scoring was reported in calcium volume rather than Agatston units, in keeping with prior studies in the field and in light of concerns regarding reproducibility of volume scoring \[[@R19]-[@R22]\].

A cutoff of 550 Hounsfield Units (HU) was used to quantify areas of calcium within the aortic valve calcification. However, given the variability in luminal enhancement inherent to contrast-induced images, in patients with a luminal attenuation \< 200 HU, a cutoff of 300 HU was used. For patients with luminal attenuation \> 500 HU, a cutoff of 50 HU greater than the luminal attenuation was used \[[@R18]\].

To analyze the aortic valve complex, the virtual basal ring was created using the double-oblique method by identifying the insertion of each of the aortic cusps at the annular plane. This technique is commonly used to size the annulus prior to TAVR procedures \[[@R23]\]. The process of how the virtual basal ring was created is depicted and described in [Figure 2a-d](#F2){ref-type="fig"}. The aortic valve complex was then batched and separated along the craniocaudal axis of the LVOT/aortic valve ([Fig. 3a](#F3){ref-type="fig"}) to exclude calcification from neighboring regions such as the aortomitral continuity. The region of interest spanned from 5 mm below the annular plane to the superior edge of the leaflets. Areas of calcification could then be individually traced by the reader and scored separately as needed after adjusting for the luminal attenuation ([Fig. 3b-d](#F3){ref-type="fig"}).

![(a) Unaligned view of the aortic annulus that is not in plane. The top-left is the axial view, bottom-left is the transverse view and the bottom-right is the sagittal view. (b) The right coronary cusp (RCC) is now visible in the axial view by adjusting the red axes. The green and purple axes are then centered on the insertion of the RCC. (c) The non-coronary cusp (NCC) insertion is aligned by adjusting the red axes in the sagittal image to bring it into plane with the RCC insertion in the axial view. (d) The purple axes are adjusted to run through both RCC and NCC insertions. Then, the red axes on the transverse view are adjusted to bring in the insertion of the left coronary cusp (LCC) into the same plane as the RCC and NCC.](cr-11-155-g002){#F2}

![(a) The aortic valve complex used for analysis is created using a batching tool to separate the study images from the larger, original. The batching tool is visible in the bottom left in the axial view as a box of green lines, and it is centered at the annular plane (red axes). It extends 5 mm caudally from the annular plane and cranially to the tip of the upper leaflets. Each green line represents 1 mm. The output at the level of the annular plane is in the top-right box, with the cusps labeled as right coronary cusp (RCC), left coronary cusp (LCC) and non-coronary cusp (NCC) for orientation. (b) Tool used to calculate mean attenuation in Hounsfield Units (HU) to adjust cutoffs for calcium scoring. In this image, the mean luminal attenuation is 456 HU, so a cutoff of 550 HU was used. (c) Zoomed in view of leaflet calcification in one slice of the upper leaflet zone for each leaflet. (d) Calcification of each leaflet in this slice in the upper leaflet zone was traced using calcium analysis software, which then provided a calcium score, volume and mean. In the device landing zone and annulus region, a total calcium score, volume and mean was provided.](cr-11-155-g003){#F3}

The following regions of the aortic valve complex were scored: the LVOT region (from 5 mm below the annular plane to the annular plane), the device-landing zone (DLZ) (2 mm inferior to the annular plane to 3 mm superior to the annular plane) and the upper leaflet region (3 mm superior to the annular plan to the superior edge of the leaflets) ([Fig. 4](#F4){ref-type="fig"}). Each leaflet was separately quantified in the upper leaflet region ([Fig. 3d](#F3){ref-type="fig"}).

![The aortic valve complex was separated in the craniocaudal axis of the left ventricular outflow tract (LVOT)/aortic valve into the following regions: the LVOT region (from 5 mm below the annular plane to the annular plane, green), the device-landing zone (2 mm inferior to the annular plane to 3 mm superior to the annular plane, yellow) and the upper leaflet region (3 mm superior to the annular plan to the superior edge of the leaflets, blue). Each leaflet was separately quantified in the upper leaflet region. NCC: non-coronary cusp; LCC: left coronary cusp; RCC: right coronary cusp.](cr-11-155-g004){#F4}

Statistics {#s2f}
----------

Data were retrospectively analyzed. All categorical variables were analyzed between the two groups using the two-tailed Fisher's exact test. Data are reported as numbers and percentages. Continuous variables were analyzed using the two-tailed unpaired Student's *t*-test and are reported as mean values and the standard deviation. Statistical analysis was performed using the STATA SE 14 Software (Stata Corp LP, College Station, TX, USA).

Ethical compliance with human study {#s2g}
-----------------------------------

The study protocol was approved by the local Institutional Review Board and adhered to the principles of the Declaration of Helsinki.

Results {#s3}
=======

Baseline characteristics {#s3a}
------------------------

The baseline characteristics of this study population, encompassing demographic, electrocardiographic, procedural and imaging data are presented in [Table 2](#T2){ref-type="table"}. Patients who did not require PPM implantation after TAVR are compared with patients who required PPM implantation after TAVR but were not pacemaker-dependent at 30 days. There were no significant differences between these two groups except for a higher rate of intra-procedural CHB in the PPM implantation group (P = 0.004). [Table 2](#T2){ref-type="table"} also compares patients who did not require PPM implantation after TAVR with patients who required PPM implantation after TAVR and were pacemaker-dependent at 30 days. One patient who did not receive a PPM post-TAVR did not have any electrocardiographic data. Patient who were pacemaker-dependent at 30 days had a significantly higher estimated glomerular filtration rate (eGFR) \< 60 (P = 0.035), higher baseline creatinine (P = 0.0002) and lower rate of hypertension than patients who did not require PPM implantation. Additionally, there was a significantly higher amount of pre-existing right bundle branch block (RBBB) (P \< 0.001), bifascicular block (P \< 0.001), QRS duration (P = 0.0002) and intra-procedural heart block (P \< 0.001).

###### Baseline Characteristics and Comparison of Patients Not Requiring PPM Implant and Those Requiring PPM Implant Post-TAVR

                                          No PPM (n = 201)   Non-RV pacing-dependent at 30 days (n = 17)   P-value   Pacing-dependent at 30 days (n = 8)   P-value
  --------------------------------------- ------------------ --------------------------------------------- --------- ------------------------------------- -----------
  Age                                     82.2 ± 8.3         80.4 ± 6.3                                    0.39      80.9 ± 8.3                            0.66
  Gender (female)                         102/201            8/17                                          0.81      2/8                                   0.28
  BMI                                     27.2 ± 6.3         29.1 ± 6.3                                    0.27      25.0 ± 4.5                            0.32
  Hypertension                            185/201            15/17                                         0.64      5/8                                   0.03
  DM                                      70/201             10/17                                         0.066     2/8                                   0.72
  CAD                                     157/201            14/17                                         0.77      5/8                                   0.38
  CHF                                     142/201            13/17                                         0.78      5/8                                   0.70
  COPD                                    37/201             2/17                                          0.55      1/8                                   1
  PVD                                     29/201             4/17                                          0.48      1/8                                   1
  History of atrial fibrillation          69/201             6/17                                          1         2/8                                   0.72
  History of atrial flutter               26/175             1/17                                          0.49      1/8                                   1
  eGFR \< 60                              97/201             10/17                                         0.46      7/8                                   0.035
  Creatinine                              1.12 ± 0.54        1.36 ± 0.61                                   0.09      1.92 ± 1.42                           0.0002
  Prior CABG                              66/201             7/17                                          0.59      2/8                                   0.73
  Prior PCI                               74/201             3/17                                          0.12      3/8                                   1
  Prior balloon valvuloplasty             25/201             5/17                                          0.065     0/8                                   0.60
  ACE-I/ARB                               106/201            7/17                                          0.45      5/8                                   0.73
  Beta-blockers                           144/201            10/17                                         0.28      6/8                                   1
  Digoxin                                 13/201             0/17                                          0.41      0/8                                   1
  Other anti-arrhythmic drugs             12/201             0/17                                          0.61      0/8                                   1
  Sinus rhythm                            161/200            11/17                                         0.21      7/8                                   1
  First-degree AV block                   42/200             3/17                                          1         2/8                                   1
  LAFB                                    27/200             4/17                                          0.28      3/8                                   0.09
  LPFB                                    1/200              1/17                                          0.15      1/8                                   0.08
  RBBB                                    18/200             2/17                                          1         8/8                                   \< 0.0001
  LBBB                                    22/200             1/17                                          0.70      0/8                                   0.60
  Bifascicular block                      9/200              2/17                                          0.21      5/8                                   \< 0.0001
  QRS duration \> 120 ms                  48/200             3/17                                          0.77      8/8                                   \< 0.0001
  QRS duration (ms)                       106.1 ± 24.2       108.4 ± 22.0                                  0.71      138.8 ± 14.1                          0.0002
  Aortic valve area                       0.66 ± 0.23        0.65 ± 0.23                                   0.78      0.77 ± 0.26                           0.19
  LVEF                                    56.4 ± 13.4        52.1 ± 13.9                                   0.21      59.4 ± 11.8                           0.53
  LVOTd                                   2.02 ± 0.22        2.04 ± 0.33                                   0.74      2.1 ± 0.22                            0.31
  Transfemoral approach                   155/201            13/17                                         1         8/8                                   0.20
  Transapical approach                    36/201             4/17                                          0.74      0/8                                   0.36
  Intra-procedural complete heart block   17/201             6/17                                          0.004     7/8                                   \< 0.0001
  Valve size                              25.0 ± 2.3         25.3 ± 2.5                                    0.60      25.3 ± 2.1                            0.75
  Valve/LVOTd                             12.5 ± 1.3         12.6 ± 1.8                                    0.71      12.1 ± 1.1                            0.38
  Percent oversizing by annulus area      11.3 ± 18.0        13.7 ± 15.3                                   0.60      -0.03 ± 12.7                          0.08

The P-values shown are derived from two-tailed Fisher's exact test for categorical variables and two-tailed unpaired Student's *t*-test for continuous variables. Patients who were non-RV pacing-dependent at 30 days and patients who were RV pacing-dependent at 30 days patients were separately compared with the non-pacemaker population to derive these P-values. Continuous variables are reported as the mean plus or minus the standard deviation. PPM: permanent pacemaker; TAVR: transcatheter aortic valve replacement; RV: right ventricular; BMI: body mass index; DM: diabetes mellitus; CAD: coronary artery disease; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; PVD: peripheral vascular disease; eGFR: estimated glomerular filtration rate; CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention; ACE-I/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor blocker; AV: atrioventricular; LAFB: left anterior fascicular block; LPFB: left posterior fascicular block; RBBB: right bundle branch block; LBBB: left bundle branch block; LVEF: left ventricular ejection fraction; LVOTd: left ventricular outflow tract diameter.

[Table 3](#T3){ref-type="table"} compares the baseline demographic and clinical characteristics between patients who were pacemaker-dependent at 30 days and patients who were not pacemaker-dependent at 30 days. There was no significant difference in baseline characteristics between these two groups.

###### Baseline Demographic and Clinical Characteristics of Non-RV Pacing-Dependent and Pacing-Dependent Patients at 1 Month Post-PPM Implant

                                   Non-RV pacing-dependent (n = 17)   RV pacing-dependent (n = 8)   P-value
  -------------------------------- ---------------------------------- ----------------------------- ---------
  Age                              80.4 ± 6.3                         80.9 ± 8.3                    0.88
  Gender (female)                  8/17                               2/8                           0.40
  BMI                              29.1 ± 6.3                         25.0 ± 4 .5                   0.12
  Hypertension                     15/17                              5/8                           0.28
  DM                               10/17                              2/8                           0.2
  CAD                              14/17                              5/8                           0.34
  CHF                              13/17                              5/8                           0.64
  COPD                             2/17                               1/8                           1
  PVD                              4/17                               1/8                           0.64
  History of atrial fibrillation   6/17                               2/8                           0.68
  History of atrial flutter        1/17                               1/8                           1
  eGFR \< 60                       10/17                              7/8                           0.21
  Creatinine                       1.36 ± 0.61                        1.92 ± 1.42                   0.19
  Prior CABG                       7/17                               2/8                           0.66
  Prior PCI                        3/17                               3/8                           0.34
  Prior balloon valvuloplasty      5/17                               0/8                           0.14
  ACE-I/ARB                        7/17                               5/8                           0.41
  Beta-blockers                    10/17                              6/8                           0.66
  Digoxin                          0/17                               0/8                           1
  Other anti-arrhythmic drugs      0/17                               0/8                           1

The P-values shown are derived from two-tailed Fisher's exact test for categorical variables and two-tailed unpaired Student's *t*-test for continuous variables. Patients who were non-RV pacing-dependent at 30 days and patients who were RV pacing-dependent at 30 days patients were separately compared with the non-pacemaker population to derive these P-values. Continuous variables are reported as the mean plus or minus the standard deviation. RV: right ventricular; PPM: permanent pacemaker; BMI: body mass index; DM: diabetes mellitus; CAD: coronary artery disease; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; PVD: peripheral vascular disease; eGFR: estimated glomerular filtration rate; CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention; ACE-I/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor blocker.

Indications for PPM implantation {#s3b}
--------------------------------

A total of 25 patients underwent PPM implantation after TAVR in this study. The most common indication for PPM implantation was CHB (80%), followed by sick sinus syndrome (SSS, 12%) and new left bundle branch block (LBBB, 8%). All patients who were pacemaker-dependent at 30 days post-TAVR received PPM implants for CHB. There was no significant difference between indications for PPM implantation between the two groups ([Table 1](#T1){ref-type="table"}).

Predictors of RV pacing requirements at 30 days after PPM implant {#s3c}
-----------------------------------------------------------------

A comparison of electrocardiographic, imaging and procedural parameters between patients who were pacemaker-dependent at 30 days after PPM implant and those who were not pacemaker-dependent at 30 days after PPM implant are reported in [Supplementary Material 1](#S1){ref-type="supplementary-material"} ([www.cardiologyres.org](http://www.cardiologyres.org)). Patients who were pacemaker-dependent at 30 days had significantly higher rates of RBBB (P ≤ 0.0001), bifascicular block (P = 0.017), QRS duration \> 120 ms (P = 0.002) and intra-procedural CHB (P = 0.03) than patients who were not pacemaker-dependent at 30 days. There was also a significant difference in QRS duration as a continuous variable (P = 0.0017). There were no echocardiographic parameters that were significantly different between the two groups ([Table 1](#T1){ref-type="table"}). Patients who were pacemaker-dependent at 30 days had significantly less oversizing of their valves than patients who were not pacemaker-dependent at 30 days (P = 0.04). There was no significant difference in the type or generation of valve between the two groups ([Table 1](#T1){ref-type="table"}).

Aortic valve calcification data for patients who were pacemaker-dependent at 30 days compared with patients who were not pacemaker-dependent at 30 days are shown in [Table 4](#T4){ref-type="table"}. There was no significant difference in mean attenuation (P = 0.72) or Hounsfield Units (HU) cutoff (P = 0.62) between the two groups. One patient who was not pacemaker-dependent at 30 days was excluded from analysis because of a pre-existing prosthetic aortic valve (valve-in-valve), which interfered with calcium quantification. Compared with patients who were not pacemaker-dependent at 30 days, patients who were pacemaker-dependent at 30 days had a significantly higher non-coronary cusp (NCC) leaflet calcium volume (P = 0.006). There was also a trend towards higher total calcium volume in the total upper leaflet zone (P = 0.07) in patients who were pacemaker-dependent at 30 days.

###### Aortic Valve Complex Calcification

                                 RV pacing-dependent at 30 days (n = 8)   Non-RV pacing-dependent at 30 days (n = 16)   P-value
  ------------------------------ ---------------------------------------- --------------------------------------------- ---------
  Mean attenuation               336.6 ± 87.6                             353.8 ± 120.2                                 0.72
  HU cutoff                      353.8 ± 70.7                             539.8 ± 66.9                                  0.62
  Total calcium volume           783.5 ± 622.1                            420.3 ± 264.2                                 0.055
  LVOT calcium volume            673.7 ± 202.8                            697.6 ± 34.7                                  0.18
  Annulus calcium volume         117.9 ± 120.6                            92.9 ± 50.4                                   0.48
  RCC leaflet calcium volume     119.7 ± 121.5                            107.2 ± 119.9                                 0.81
  NCC leaflet calcium volume     342.0 ± 290.8                            113.6 ± 63.2                                  0.006
  LCC leaflet calcium volume     139.9 ± 132.7                            91.4 ± 87.0                                   0.29
  Total leaflet calcium volume   601.6 ± 504.9                            312.2 ± 248.8                                 0.07

The P-values shown are derived from two-tailed unpaired Student's *t*-test for continuous variables. Patients who were non-RV pacing-dependent at 30 days and patients who were RV pacing-dependent at 30 days patients were separately compared. Continuous variables are reported as the mean plus or minus the standard deviation. HU: Hounsfield Units; LVOT: left ventricular outflow tract; RCC: right coronary cusp; NCC: non-coronary cusp; LCC: left coronary cusp; RV: right ventricular.

The distribution of calcium volume in the leaflet region was similar between the two groups, with about half of the leaflet calcium located in the NCC. Calcium distribution in the leaflet zone was not significantly associated with pacemaker dependence at 30 days ([Supplementary Material 1](#S1){ref-type="supplementary-material"}, [www.cardiologyres.org](http://www.cardiologyres.org)).

All patients who were pacemaker-dependent at 30 days post-implant had pre-existing RBBBs, while only two out of 17 patients who were not pacemaker-dependent at 30 days post-implant had pre-existing RBBBs (odds ratio (OR) 105.4, 4.52 - 2458.5, P = 0.004). The presence of a pre-existing bifascicular block (OR 12.50, 1.6 - 97.65, P = 0.02), QRS duration \> 120 ms (OR 70.43, 3.23 - 1535.22, P = 0.007) and intra-procedural CHB (OR 12.83, 1.26 - 130.52, P = 0.03) were also strongly associated with pacemaker dependence at 30 days ([Table 5](#T5){ref-type="table"}). The positive predictive value of RBBB in determining pacemaker dependence pacing at 30 days was 88.2%.

###### Predictors of Persistent RV Pacing After PPM Implantation

                                          RV pacing-dependent (n = 8)   Non-RV pacing-dependent (n = 17)   Odds ratio (95% CI)       P-value
  --------------------------------------- ----------------------------- ---------------------------------- ------------------------- ---------
  RBBB                                    8/8                           2/17                               105.4 (4.52 - 2,458.5)    0.004
  Bifascicular block                      5/8                           2/17                               12.50 (1.6 - 97.65)       0.02
  QRS duration \> 120 ms                  8/8                           3/17                               70.43 (3.23 - 1,535.22)   0.007
  Intra-procedural complete heart block   7/8                           6/17                               12.83 (1.26 - 130.52)     0.03
  NCC volume \> 239.2 mm^3^               6/8                           0/16                               85.80 (3.61 - 2,041.00)   0.006

The P-values shown are derived from two-tailed Fisher's exact test for categorical variables. Patients who were non-RV pacing-dependent at 30 days and patients who were RV pacing-dependent at 30 days patients were separately compared. RBBB: right bundle branch block; CI: confidence interval; NCC: non-coronary cusp; RV: right ventricular; PPM: permanent pacemaker.

[Figure 5](#F5){ref-type="fig"} shows the receiver operating characteristic (ROC) curve for NCC calcium volume and pacemaker dependence at 30 days. Using a cutoff of \> 239 mm^3^, calcium volume in the NCC leaflet was predictive of pacemaker dependence at 30 days (AUC = 0.813).

![The receiver operating characteristic (ROC) curve for non-coronary cusp (NCC) volume and pacemaker dependence at 30 days. A cutoff of 239.2 mm^3^ for calcium was used.](cr-11-155-g005){#F5}

Pacemaker follow-up {#s3d}
-------------------

Twenty-five patients received pacemakers after TAVR in this study. Within 10 days of pacemaker implantation, there were nine patients (36%) who were no longer pacemaker-dependent. At 30 days post-PPM implantation, 17 patients (68%) were no longer pacemaker-dependent ([Fig. 1](#F1){ref-type="fig"}). Non-paced surface ECGs for the 17 patients who were not pacemaker-dependent at 30-day follow-up showed recovery back to their pre-TAVR rhythm in all but one patient, who had developed new first-degree AV block at follow-up.

Patients with early recovery of cardiac conduction {#s3e}
--------------------------------------------------

To further characterize the nine patients with evidence of early recovery of cardiac conduction, these nine patients were compared with the remaining eight patients who were no longer pacemaker-dependent at 30 days and the eight patients who remained pacemaker-dependent at 30 days. Pre-existing RBBB, pre-existing bifascicular block, pre-existing QRS duration \> 120 ms and intra-procedural CHB were all still significantly different between the non-RV pacing-dependent patients at 10 days when compared with the RV pacing-dependent patients at 10 days. There were no significant differences between demographic, electrocardiographic, imaging, or procedural parameters between the nine patients with early recovery of their conduction system at 10 days and the eight non-RV pacing-dependent patients with late recovery of their conduction system at 30 days ([Supplementary Material 2](#S2){ref-type="supplementary-material"}, [www.cardiologyres.org](http://www.cardiologyres.org)).

Calcium scoring was also compared among patients who had early recovery of their conduction, patients who had late recovery of their cardiac conduction and patients who did not have recovery of their cardiac conduction at all. One patient was excluded from the calcium scoring analysis, as in the prior analysis, because of a prior valve-in-valve procedure. There were no significant differences in calcium scoring between patients with early and late recovery of their conduction. However, both groups had a significantly lower NCC volume than patients with no recovery of their conduction system ([Supplementary Material 3](#S3){ref-type="supplementary-material"}, [www.cardiologyres.org](http://www.cardiologyres.org)).

Discussion {#s4}
==========

This single-center study of 262 consecutive patients who underwent TAVR with a balloon-expandable valve at a single institution builds on our previous findings in describing predictors of persistent cardiac conduction abnormalities after TAVR and introduces aortic valve calcification as a novel predictor of pacemaker dependence. As described previously, conduction abnormalities after TAVR are often transient and resolve over time. Out of 25 patients (9.5%) who received PPM implants, 36% of patients were no longer pacemaker-dependent 10 days after implantation and 68% of patients were no longer pacemaker-dependent at 30 days post-implantation. Electrocardiographic parameters such as RBBB, bifascicular block, QRS duration and intra-procedural CHB were predictive of pacemaker dependence at 30 days \[[@R13]\].

Aortic valve calcification in the NCC leaflet was found to be significantly associated with pacemaker dependence at 30 days. This novel predictor had a strong predictive value for pacemaker dependence at 30 days. Using a cutoff of \> 239 mm^3^, NCC leaflet calcium volume was strongly predictive of pacemaker dependence at 30 days post-implant, with an AUC of 0.813. Distribution of aortic valve complex calcification was not associated with pacemaker dependence; rather, only the absolute calcium volume was predictive.

Calcification of the aortic valve complex by CT scan has been studied as a predictor for PPM implantation after TAVR. Fujita et al examined patients who received either balloon-expandable valves or self-expanding valves and found that left coronary cusp (LCC) leaflet calcification as well as DLZ calcification was significantly associated with the need for new pacemaker implantation after TAVR \[[@R24]\]. In a separate study, Maeno et al found that calcification in the NCC portion of the DLZ, as well as LCC and RCC leaflet calcification, was predictive of need for new PPM implantation after TAVR with third-generation balloon-expandable valves \[[@R07]\]. These findings suggest that aortic valve complex calcification does play a role in conduction abnormalities after TAVR, though it is unclear exactly what distribution portends the highest risk. Furthermore, it is unclear whether aortic valve complex calcification or the specific distribution of calcification plays a role in long-term conduction abnormalities after TAVR.

Prior to the routine use of CT scans in TAVR pre-procedure planning, 3D transesophageal echocardiography (TEE) was a frequently used imaging modality to further visualize the aortic valve complex. NCC thickness was found to be an important predictor of PPM implantation after TAVR with self-expanding valves \[[@R25]\]. The NCC lies in close proximity to the conduction system, as the left bundle courses in the interleaflet region between the NCC and RCC with the AV node close by \[[@R25], [@R26]\]. In fact, this relationship between the NCC and AV node has been used during catheter ablation of the AV node \[[@R27], [@R28]\]. Because the native aortic valve is not removed during TAVR but merely excluded, increased pressure on this interleaflet region during balloon expansion of the bioprosthetic valve expansion can lead to damage to the conduction system, which may be exacerbated by significant calcification of the adjacent NCC.

Interestingly, while NCC calcium volume was a strong predictor of eventual conduction system recovery, there was no significant difference in NCC calcium volume between patients with early and late recovery of their conduction system ([Supplementary Material 3](#S3){ref-type="supplementary-material"}, [www.cardiologyres.org](http://www.cardiologyres.org)). Furthermore, demographic, electrocardiographic, imaging and procedural parameters were not significantly different between these groups either ([Supplementary Material 2](#S2){ref-type="supplementary-material"}, [www.cardiologyres.org](http://www.cardiologyres.org)). This likely reflects the fact that conduction disease after TAVR is influenced by a multitude of factors, including pre-existing conduction disease, intra-procedural complications, anatomy, sizing and calcification. However, given the small sample size of this study, a multivariate analysis for these subgroups would not be statistically valid and was not performed. Future studies with larger sample sizes may help clarify this issue further.

Because conduction abnormalities after TAVR often resolve over time, it is of particular interest to determine which patients will recover conduction and which patients will continue to have conduction abnormalities after TAVR. Interestingly, in our study, intra-procedural heart block was the only significant difference between patients who did not require PPM implantation after TAVR and those who required PPM implantation but were not pacemaker-dependent at 30 days. In contrast, patients who were pacemaker-dependent at 30 days had significantly higher rates of RBBB, intra-procedural heart block, bifascicular block and QRS duration than those who did not require PPM implantation ([Table 2](#T2){ref-type="table"}). One possible explanation for the similarity of patients who do not require PPM after TAVR and those who require PPM but are not pacemaker-dependent at 30 days is that the acute need for pacemaker in these patients is related to procedural related factors such as edema and mechanical injury. In contrast, patients who are pacemaker-dependent at 30 days have greater pre-existing conduction disease.

As with any other invasive procedure, PPM implantation is not benign, and PPM removal after implantation is not recommended solely because of recovery of conduction abnormalities \[[@R29], [@R30]\]. Furthermore, multiple studies have shown that long-term RV pacing is associated with worsening ejection fraction and congestive heart failure due to the loss of ventricular synchrony, which leads to increased morbidity and mortality \[[@R31]-[@R35]\]. PPM after TAVR has been associated with increased repeat hospitalizations, increased morbidity and mortality and decrease in left ventricular ejection fraction \[[@R15], [@R16], [@R36]\].

At the same time, while conduction abnormalities after TAVR may be temporary in many cases, it is unlikely that patients will be kept in the hospital long enough to allow complete recovery of the conduction system and avoid PPM implantation. However, identification of patients at high or low risk of permanent conduction abnormalities would be helpful in determining the optimal pacing strategies for these patients. For example, patients with a low risk of permanent conduction abnormalities may only require a singular ventricular lead for backup pacing, while patients with a high risk of permanent abnormalities would warrant more aggressive device implantation and pacing strategies.

Limitations {#s4a}
-----------

The major limitations of this study are the mono-centric study design as well as the relatively small sample size. The rate of pacemaker implantation in this study (11.1%) is slightly higher than that reported in other large studies of balloon-expandable valve implantation (8.8%) \[[@R15]\]. The exact intra-procedural implant depth, which has been associated with pacemaker implantation in a few studies, was not reported at the time of the procedure and not analyzed in this study \[[@R37], [@R38]\]. Furthermore, although rates of pacemaker implantation vary slightly across different generations of the SAPIEN valve, predictors were not analyzed separately based on valve generation in this study because of the small sample size. Clinical outcomes, such as mortality, LVEF and re-hospitalization were not assessed in this study. Finally, aortic valve calcification was not quantified at the time of the study and was analyzed retrospectively. Future multicenter studies will help to create prediction models to identify patients at risk of long-term conduction abnormalities after TAVR.

Conclusion {#s4b}
----------

In this single-center study, conduction disturbances after TAVR with a balloon-expandable valve requiring pacemaker implantation recovered in the majority of patients (68%) at 30 days post-PPM implantation. NCC leaflet calcification as quantified by pre-TAVR CT was found to be a novel and powerful predictor of pacemaker dependence after TAVR. As indications for TAVR expand to younger and lower risk patients, it will become increasingly important to develop accurate prediction models for conduction abnormalities after TAVR to determine optimal pacing strategies in this growing patient population.
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